Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chronic hepatitis B: Update 2009

Chronic hepatitis B: Update 2009 The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B are now posted online at www.aasld.org . This is the fourth version of this guideline; the last version was published in 2007. 1 Abbreviations HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus. The key changes in the 2009 version are new recommendations for first‐line and second‐line antiviral agents. Since the last update, tenofovir disoproxil fumarate (Viread) was approved by the U.S. Food and Drug Administration for treatment of chronic hepatitis B based on the results of two double‐blind randomized trials showing a superiority of tenofovir compared to adefovir. In the trial on patients positive for hepatitis B e antigen (HBeAg), 48 weeks of treatment with tenofovir resulted in a significantly higher proportion of patients with undetectable serum hepatitis B virus (HBV) DNA assay by polymerase chain reaction (76% versus 13%), alanine aminotransferase normalization (68% versus 54%), and hepatitis B surface antigen loss (3% versus 0%), with similar rates of histologic response (74% versus 68%) and HBeAg seroconversion (21% versus 18%) compared to treatment with adefovir. 2 In the trial on HBeAg‐negative http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hepatology Wiley

Chronic hepatitis B: Update 2009

Lok, Anna S. F.; McMahon, Brian J.
Hepatology , Volume 50 (3) – Sep 1, 2009
Download PDF
2 pages

Loading next page...
 
/lp/wiley/chronic-hepatitis-b-update-2009-YbKQuyqFjN

References (321)

Publisher
Wiley
Copyright
Copyright © 2009 American Association for the Study of Liver Diseases
ISSN
0270-9139
eISSN
1527-3350
DOI
10.1002/hep.23190
pmid
19714720
Publisher site
See Article on Publisher Site

Abstract

The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B are now posted online at www.aasld.org . This is the fourth version of this guideline; the last version was published in 2007. 1 Abbreviations HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus. The key changes in the 2009 version are new recommendations for first‐line and second‐line antiviral agents. Since the last update, tenofovir disoproxil fumarate (Viread) was approved by the U.S. Food and Drug Administration for treatment of chronic hepatitis B based on the results of two double‐blind randomized trials showing a superiority of tenofovir compared to adefovir. In the trial on patients positive for hepatitis B e antigen (HBeAg), 48 weeks of treatment with tenofovir resulted in a significantly higher proportion of patients with undetectable serum hepatitis B virus (HBV) DNA assay by polymerase chain reaction (76% versus 13%), alanine aminotransferase normalization (68% versus 54%), and hepatitis B surface antigen loss (3% versus 0%), with similar rates of histologic response (74% versus 68%) and HBeAg seroconversion (21% versus 18%) compared to treatment with adefovir. 2 In the trial on HBeAg‐negative

Journal

Hepatology – Wiley

Published: Sep 1, 2009

There are no references for this article.